Marquez-Vazquez Juan Francisco, Arellano-Saldaña María Elena, Rojas-Martinez Karla Nayeli, Carrillo-Mora Paul
Master and Doctorate Division, Instituto Nacional de Rehabilitación LGII, Tlalpan, México.
Pediatric Rehabilitation Service, Instituto Nacional de Rehabilitación LGII, Tlalpan, México.
Front Rehabil Sci. 2022 Jun 16;3:875235. doi: 10.3389/fresc.2022.875235. eCollection 2022.
The aim of this study was to compare the effects of intraglandular abobotuliniumtoxinA application and oromotor therapy in the management of sialorrhea in patients with cerebral palsy and its effect on sleep quality.
A comparative study ( = 134), mean age 7.1 years (± 3.9 years) was performed in pediatric patients, between the efficacy of abobotuliniumtoxinA in salivary glands and oromotor therapy (JT), with a control group receiving exclusive oromotor therapy (EOMT). Demographic variables, as well as Gross Motor Function Classification System (GMFCS), Drooling Severity and Frequency Scale (DSFS), Sleep Disturbance Scale for Children (SDSC) and Eating and Drinking Ability Classification System (EDACS) were analyzed in 134 patients considering two measurements 6 months apart. Statistical analysis was developed between both groups.
The greatest improvement in safety and efficacy of swallowing were those in the JT group with initial levels of EDACS IV and V. Both therapies result in favorable changes of all subscales means of SDSC, with joint therapy showing the greater benefit ( = 0.003) over EOMT ( = 0.06), especially for Sleep Breathing Disorders and Disorders of initiating and maintaining sleep ( < 0.01 vs. = 0.07). No major adverse effects were found, only those expected from the application of the toxin, such as pain, mild, and transient local inflammation.
A correlation between frequency and intensity of sialorrhea, with the frequency of sleep disorders and dysphagia was found. Conventional EOMT proved to be useful, improving the safety and efficacy of swallowing, sialorrhea and sleep disorder, however it can be enhanced with the application of abobotuliniumtoxinA.
本研究旨在比较腺体内注射阿泊肉毒素A与口运动疗法对脑瘫患者流涎的治疗效果及其对睡眠质量的影响。
对134例平均年龄7.1岁(±3.9岁)的儿科患者进行了一项对比研究,比较阿泊肉毒素A在唾液腺治疗中的疗效与口运动疗法(JT),对照组接受单纯口运动疗法(EOMT)。对134例患者进行了人口统计学变量分析,以及粗大运动功能分类系统(GMFCS)、流涎严重程度和频率量表(DSFS)、儿童睡眠障碍量表(SDSC)和进食与饮水能力分类系统(EDACS)分析,两次测量间隔6个月。对两组进行了统计学分析。
吞咽安全性和疗效改善最大的是初始EDACS水平为IV和V级的JT组。两种疗法均使SDSC所有子量表均值发生有利变化,联合治疗比EOMT显示出更大益处(P = 0.003对P = 0.06),尤其是在睡眠呼吸障碍和入睡及维持睡眠障碍方面(P < 0.01对P = 0.07)。未发现重大不良反应,仅出现毒素应用预期的不良反应,如疼痛、轻度短暂局部炎症。
发现流涎频率和强度与睡眠障碍频率及吞咽困难之间存在相关性。传统的EOMT被证明是有用的,可改善吞咽安全性和疗效、流涎及睡眠障碍,然而阿泊肉毒素A的应用可增强其效果。